CRB-913
Asset
Peripherally restricted cannabinoid CB1 receptor inverse agonist intended to reduce body weight.
- Stage
- Phase 1
- Modality
- Small molecule
- Target
- CNR1
- 1
- Indication
- 1
- Trial
- 1
- Developer
Indications
1Obese but otherwise healthy participants
Phase 1, Completed, NCT07310901, clinicaltrials.gov, 13 Oct 2026
In the full profile
- Targets and what it contains1
- Owner and partners1
- Trials1
- Evidence for its targets1
- Competitors5
- Signals2
Every asset’s record: target, stage, trials and the evidence behind it.